UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2020

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

COMMISSION FILE NUMBER: 000-55753

 

Can B̅ Corp.

(Exact name of registrant as specified in its charter)

 

Florida		20-3624118
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

960 South Broadway, Suite 120

Hicksville, NY 11801

(Address of principal executive offices)

 

516-595-9544

(Registrant’s telephone number, including area code)

 

Canbiola, Inc.

(Former name, former address and former fiscal, if changed since last report)

 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Tile of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		CANB		N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	[  ]	Accelerated filer	[  ]
Non-accelerated filer	[X]	Smaller reporting company	[X]
Emerging Growth Company	[  ]
(Do not check if smaller reporting company)

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [  ] Yes [X] No

 

The number of shares of the registrant’s only class of common stock issued and outstanding as of November 9, 2020 was 4,915,173 shares.

 

 

 

Can B Corp

FORM 10-Q

September 30, 2020

 

TABLE OF CONTENTS

 

		Page No.
PART I. - FINANCIAL INFORMATION
Item 1.	Financial Statements
	Consolidated Balance Sheets September 30, 2020 and December 31, 2019	3
	Consolidated Statements of Operations – Three and Nine Months Ended September 30, 2020 and 2019	4
	Consolidated Statement of Stockholders’ Deficiency Nine months ended September 30, 2020 and 2019	5
	Consolidated Statements of Cash Flows – Nine Months Ended September 30, 2020 and 2019	6
	Condensed Notes to Unaudited Consolidated Financial Statements.	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	24
Item 3	Quantitative and Qualitative Disclosures About Market Risk.	26
Item 4	Controls and Procedures.	26
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	26
Item A.	Risk Factors	26
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26
Item 3.	Defaults Upon Senior Securities	28
Item 4.	Mine Safety Disclosures	28
Item 5.	Other Information	28
Item 6.	Exhibits	28

 

 

PART 1 - FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

Can B̅ Corp. and Subsidiary

Consolidated Balance Sheets

 

		(Unaudited) September 30,				December 31,
		2020				2019
Assets
Current assets:
Cash and cash equivalents		$	45,506			$	46,540
Accounts receivable, less allowance for doubtful accounts of $455,620 and $253,483, respectively			1,740,147				1,251,609
Inventory			914,129				784,497
Note Receivable			22,787				24,268
Prepaid expenses - current			1,246,637				1,279,901
Total current assets			3,969,206				3,386,815
Property and equipment, at cost less accumulated depreciation of $209,554 and $116,555, respectively			1,025,859				1,075,242
Other assets:
Deposit - noncurrent			21,287				21,287
Prepaid expenses - noncurrent			298,104				1,179,929
Other receivable – noncurrent			24,492				58,206
Intangible assets, net of accumulated amortization of $649,077 and $202,521, respectively			811,193				1,056,562
Goodwill			55,849				55,849
Right-of-Use Asset, net of amortization of $35,024 and $6,280, respectively			68,236				96,980
Total other assets			1,279,161				2,468,813
Total assets		$	6,274,226			$	6,930,870
Liabilities and Stockholders’ Deficiency
Current liabilities:
Accounts payable			447,628				226,467
Accrued officers’ compensation			279,319				144,363
Other accrued expenses payable			91,113				61,557
Notes and loans payable			1,225,898				35,000
Current portion of lease liability			42,322				38,281
Total current liabilities			2,086,280				505,668
Long-term liabilities:
Non-current portion of lease liability			26,778				58,998
Notes and loans payable			354,840				-
Total long-term liabilities			381,618				58,998
Total liabilities			2,467,898				564,666
Commitments and contingencies (Notes 15)
Stockholders’ equity:
Preferred stock, authorized 5,000,000 shares:
Series A Preferred stock, no par value:
authorized 20 shares, issued and outstanding 20 shares, respectively			5,539,174				5,539,174
Common stock, no par value; authorized 1,500,000,000 shares, issued and outstanding 3,786,338 and 2,680,937 shares, respectively			24,711,409				23,113,077
Additional Paid-in capital			872,976				872,976
Additional Paid-in capital – Stock Options (Note 12)			202,200				202,200
Treasury stock			(560,000	)			-
Accumulated deficit			(26,959,431	)			(23,361,223	)
Total stockholders’ equity			3,806,328				6,366,204
Total liabilities and stockholders’ equity		$	6,274,226			$	6,930,870

 

See notes to consolidated financial statements.

 

 

Can B̅ Corp and Subsidiary

Consolidated Statements of Operations

(Unaudited)

 

		Nine Months Ended September 30,								Three Months Ended September 30,
		2020				2019				2020				2019
Revenues
Product Sales		$	1,233,287			$	1,760,761			$	459,196			$	613,622
Service Revenue			1,000				5,400				300				1,800
Total Revenues			1,234,287				1,766,161				459,496				615,422
Cost of product sales			239,975				703,607				70,381				141,850
Gross Profit			994,312				1,062,554				389,115				473,572
Operating costs and expenses:
Officers and director’s compensation (including stock-based compensation of $916,386, $1,018,786, $293,715 and $184,556, respectively)			1,306,222				1,717,586				376,565				442,898
Consulting fees (including stock-based compensation of $457,377, $1,372,181, $104,261 and $418,267, respectively)			559,483				1,540,441				136,461				449,355
Advertising expense			350,334				220,373				90,299				66,611
Hosting expense			17,587				11,389				5,451				3,472
Rent expense			193,069				155,192				71,417				67,520
Professional fees			401,419				194,468				76,283				82,452
Depreciation of property and equipment			12,357				8,687				4,254				3,157
Amortization of intangible assets			446,556				12,127				169,398				4,967
Reimbursed Expenses			61,934				168,260				20,971				70,905
Other			649,453				578,775				210,652				217,499
Total operating expenses			3,998,414				4,607,298				1,161,751				1,408,836
Loss from operations			(3,004,102	)			(3,544,744	)			(772,636	)			(935,264	)
Other income (expense):
Interest income			645				519				204				202
Gain (loss) on investment			(40,000	)			-				10,000				-
Interest expense (including amortized finance cost of $531,835, $0, $462,190 and $0, respectively)			(551,581	)			(6,879	)			(468,799	)			(6,037	)
Other income (expense) - net			(590,936	)			(6,360	)			(458,595	)			(5,835	)
Loss before provision for income taxes			(3,595,038	)			(3,551,104	)			(1,231,231	)			(941,099	)
Provision for income taxes			3,170				-				1,945				-
Net Loss		$	(3,598,208	)		$	(3,551,104	)		$	(1,233,176	)		$	(941,099	)
Net loss per common share - basic		$	1.16	)		$	(1,85	)		$	(0.37	)		$	(0.43	)
Net loss per common share - diluted		$	(0.96	)		$	(1,30	)		$	(0.31	)		$	(0.32	)
Weighted average common shares outstanding –
Basic			3,091,866				1,919,543				3,376,610				2,202,567
Diluted			3,758,546				2,724,442				4,043,290				2,962,167

 

See notes to consolidated financial statements.

 

 

Can B̅ Corp. and Subsidiary

Consolidated Statements of Stockholders’ Deficiency (Unaudited)

 

																																										Additional
		Preferred Stock A								Preferred Stock B								Preferred Stock C								Common Stock, no								Treasury								Paid-in
		, no par value								, $0.001 par value								, $0.001 par value								par value								Stock								Accumulated
		Shares				Amount				Shares				Amount				Shares				Amount				Shares				Amount				Shares				Amount				Capital				Deficit				Total
Nine Months Ended September   30, 2020
Balance, January 1, 2020			20			$	5,539,174				-			$	-				-			$	-				2,680,937			$	23,113,077				-			$	-			$	1,075,176			($	23,361,223	)		$	6,366,204
Issuance of common stock in  2020 for services rendered																											435,888				401,059																				401,059
Issuance of common stock in  2020 for 300:1 reverse stock split rounding																											2,460				-																				-
Issuance of common stock in 2020 pursuant to First Fire  note agreement																											119,508				295,780																				295,780
Issuance of common stock in 2020 pursuant to Labrys Fund Equities note agreement																											142,545				80,182																				80,182
Issuance of common stock in 2020 pursuant to Eagle Equities  note agreement																											20,000				8,745																				8,745
Issuance of common stock in 2020 for acquisition of intangible assets																											235,000				201,187																				201,187
Issuance of common stock in 2020 for compensation																											30,000				41,625																				41,625
Issuance of common stock in  2020 for interest																											185,000				77,775																				77,775
Issuance of common stock in 2020 for inventory																											478,715				491,979																				491,979
Treasury stock acquired in 2020																											(543,715	)			-				543,715				(560,000	)											(560,000	)
Net Loss																																															(3,598,208	)			(3,598,208	)
Balance, September 30, 2020			20			$	5,539,174				-			$	-				-			$	-				3,786,338			$	24,711,409				543,715			$	(560,000	)		$	1,075,176			$	(26,959,431	)		$	3,806,328
Nine Months Ended September 30, 2019
Balance, January 1, 2019			18			$	4,557,424				499,958			$	479				-			$	-				1,468,554			$	16,624,557				-			$	-			$	1,075,176			$	(18,768,753	)		$	3,488,883
Issuance of common stock for retirement of Series A  Preferred Stock			(1	)			(10,500	)																			33,333				10,500																				-
Issuance of common stock for retirement of Series B Preferred Stock											(157,105	)			(157	)											67,405				157
Sale of common stock in Q1 Q2 & Q3 2019																											379,555				3,296,700																				3,296,700
Issuance of common stock in 2019 for acquisition of  technology																											68,580				648,655																				648,655
Issuance of common stock in 2019 for satisfaction of accrued  salaries																											2,227				54,340																				54,340
Issuance of common stock in 2019 for compensation and services rendered																											212,131				1,552,755																				1,552,755
Issuance of Series A Preferred stock pursuant to employment agreement			3				992,250																																												992,250
Net loss																																															(3,551,104	)			(3,551,104	)
Balance, September 30, 2019			20			$	5,539,174				342,853			$	322				-			$	-				2,231,785			$	22,187,664				-			$	-			$	1,075,176			$	(22,319,857	)		$	6,482,479

 

See notes to consolidated financial statements.

 

 

Can B̅ Corp. and Subsidiary

Consolidated Statements of Cash Flows (Unaudited)

 

		Nine Months Ended September 30,
		2020				2019
Operating Activities:
Net loss		$	(3,598,208	)		$	(3,551,104	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation, net of prepaid stock- based consulting fees			1,373,763				2,390,967
Stock-based interest expense			390,430				-
Depreciation of property and equipment-General			12,357				8,687
Depreciation of property and equipment-COGS			80,642				49,390
Amortization of intangible assets			446,556				12,127
Amortization of original-issue-discount			141,404				-
Bad debt expense			202,137				-
Changes in operating assets and liabilities:
Accounts receivable			(690,675	)			(956,353	)
Inventory			362,348				(14,095	)
Prepaid expenses			(15,990	)			(6,226	)
Security deposit			-				28,940
Other receivable			33,714				(31,225	)
Right-of-use asset			565				580
Accounts payable			221,161				9,482
Accrued officer’s compensation			134,956				-
Other accrued expenses payable			29,556				645
Net cash used in operating activities			(875,284	)			(2,058,185	)
Investing Activities:
Note receivable			1,481				-
Fixed assets additions			(43,616	)			(1,017,300	)
Intangible assets additions			-				(550,000	)
Net cash used in investing activities			(42,135	)			(1,567,300	)
Financing Activities:
Proceeds received from notes and loans payable			1,667,840				5,000
Repayments of notes and loans payable			(90,000	)			(12,894	)
Note payable finance cost			(101,455	)			-
Acquisition of treasury stock			(560,000	)			-
Proceeds from sale of common stock			-				3,296,700
Net cash provided by financing activities			916,385				3,288,806
Increase (Decrease) in cash and cash equivalents			(1,034	)			(336,679	)
Cash and cash equivalents, beginning of period			46,540				807,747
Cash and cash equivalents, end of period		$	45,506			$	471,068
SUPPLEMENTAL CASH FLOW INFORMATION:
Income taxes paid		$	3,170			$	-
Interest paid		$	19,746			$	6,879
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock in acquisition of note payable (interest expense)		$	390,430			$	-
Issuance of common stock in acquisition of note payable (commitment shares)		$	72,052			$	-
Amortization of prepaid issuance of common Stock for services rendered		$	931,079			$	497,220
Issuance of common stock in acquisition of intangible assets		$	201,187			$	648,655
Issuance of common stock in satisfaction of officer’s compensation		$	-			$	54,340
Issuance of common stock in acquisition of inventory		$	491,980			$	-

 

See notes to consolidated financial statements

 

 

Can B̅ Corp. and Subsidiary

Notes to Consolidated Financial Statements

Nine Months Ended September 30, 2020 and 2019

 

NOTE 1 – Organization and Description of Business

 

Can B̅ Corp. was originally incorporated as WrapMail, Inc. (“WRAP”) in Florida on October 11, 2005. Effective January 5, 2015, WRAP acquired 100% ownership of Prosperity Systems, Inc. (“Prosperity”), a New York corporation incorporated on April 2, 2008. The Company is in the process of dissolving Prosperity. The Company acquired 100% of the membership interests in Pure Health Products, LLC, a New York limited liability company (“PHP” or “Pure Health Products”) effective December 28, 2018. The Company’s durable equipment products, such as sam® units with and without CBD infused pads, are marketed and sold through its wholly-owned subsidiaries, Duramed Inc. (incorporated on November 29, 2018) and DuramedNJ LLC (incorporated on May 29, 2019) (collectively, “Duramed”). Duramed began operating on or about February1, 2019. The Company’s hemp farming business is run through Green Grow Farms, Inc. (“Green Grow Farms”), which was acquired in August, 2019. The Company’s other subsidiary companies do not currently have operations.

 

Effective December 27, 2010, WRAP effected a 10-for-1 forward stock split of its common stock. Effective June 4, 2013, WRAP effected a 1-for-10 reverse stock split of its common stock. Effective March 6, 2020 Can B̅ Corp effected a 300:1 reverse stock split of its common stock.

 

On May 15, 2017, WRAP changed its name to Canbiola, Inc. On January 16, 2020 Canbiola, Inc. changed its name to Can B̅ Corp. (the “Company”, “we”, “us”, “our”, “CANB”, “Can B̅” or “Registrant”).

 

Can B̅ specializes in the production and sale of a variety of hemp-derived cannabidiol (“CBD”) products such as oils, creams, moisturizers, isolate, gel caps, spa products, and concentrates and non-hemp lifestyle products. Can B̅ is developing its own line of proprietary products as well as seeking synergistic value through acquisitions in the hemp industry. Can B̅ aims to be the premier provider of the highest quality hemp CBD products on the market through sourcing the very best raw material and developing a variety of products we believe will improve people’s lives in a variety of areas.

 

For the periods presented, the assets, liabilities, revenues, and expenses are those of CAN B and its operational subsidiaries. Financial information for PHP, Duramed and Green Grow Farms in the periods have been consolidated with the Company’s financials. Prosperity, Radical Tactical and NY Hemp Depot had no activity for the periods presented.

 

NOTE 2 – Going Concern Uncertainty

 

The consolidated financial statements have been prepared on a “going concern” basis, which contemplates the realization of assets and liquidation of liabilities in a normal course of business. As of September 30, 2020, the Company had cash and cash equivalents of $45,506 and a working capital of $1,882,926. For the periods ended September 30, 2020 and 2019, the Company had net loss of $3,598,208 and $3,551,104, respectively. These factors raise substantial doubt as to the Company’s ability to continue as a going concern. The Company plans to improve its financial condition by raising capital through sales of shares of its common stock. Also, the Company plans to expand its operation of CBD products to increase its profitability. The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

 

 

NOTE 3 – Summary of Significant Accounting Policies

 

(a) Principles of Consolidation

 

The consolidated financial statements include the accounts of CANB and its wholly-owned subsidiaries, Pure Health Products, Duramed, Prosperity Radical Tactical and Green Grow Farms. All intercompany balances and transactions have been eliminated in consolidation.

 

(b) Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

 

(c) Fair Value of Financial Instruments

 

The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, notes receivable, notes and loans payable, accounts payable, and accrued expenses payable. Except for the noncurrent note receivable, the fair value of these financial instruments approximate their carrying amounts reported in the balance sheets due to the short term maturity of these instruments. Based on comparable instruments with similar terms, the fair value of the noncurrent note receivable approximates its carrying value.

 

Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

 

Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

 

Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

 

Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

 

(d) Cash and Cash Equivalents

 

The Company considers all liquid investments purchased with a maturity of three months or less to be cash equivalents.

 

(e) Accounts receivable

 

Accounts receivable are presented in the balance sheet net of the allowance for doubtful accounts. Accounts receivable are written off when they are determined to be uncollectible. The allowance for doubtful accounts is estimated based on the Company’s historical losses, the existing economic conditions in the industry, and the financial stability of its customers. Bad debt expense was $202,137 and $0 for the periods ended September 30, 2020 and 2019.

 

(f) Inventory

 

Inventories consist of raw materials and finished goods and are stated at the lower of cost or net realizable value. Cost is principally determined using the first-in, first-out (FIFO) method.

 

 

(g) Prepaid expenses

 

Prepaid expenses include stock-based officer, employee and consulting compensation of $1,225,887 and $2,784,450 at September 30, 2020 and 2019, respectively. The Company’s policy is to record stock-based compensation as prepaids and expense over the term of employment and consulting agreements.

 

(h) Property and Equipment, Net

 

Property and equipment, net, is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repairs are charged to operations as incurred.

 

(i) Intangible Assets, Net

 

Intangible assets, net, are stated at cost less accumulated amortization. Amortization is calculated using the straight-line method over the estimated economic lives of the respective assets.

 

(j) Goodwill

 

The Company does not amortize goodwill, but instead tests for impairment at least annually. When conducting the annual impairment test for goodwill, the Company compares the estimated fair value of a reporting unit containing goodwill to its carrying value. If the estimated fair value of the reporting unit is determined to be less than its carrying value, goodwill is reduced, and an impairment loss is recorded.

 

(k) Long-lived Assets

 

The Company reviews long-lived assets held and used, intangible assets with finite useful lives and assets held for sale for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation of recoverability is required, the estimated undiscounted future cash flows associated with the asset is compared to the asset’s carrying amount to determine if a write-down is required. If the undiscounted cash flows are less than the carrying amount, an impairment loss is recorded to the extent that the carrying amount exceeds the fair value.

 

(l) Revenue Recognition

 

The Company recognizes revenue in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, which requires that five basic steps be followed to recognize revenue: (1) a legally enforceable contract that meets criterial standards as to composition and substance is identified; (2) performance obligations relating to provision of goods or services to the customer are identified; (3) the transaction price, with consideration given to any variable, noncash, or other relevant consideration, is determined; (4) the transaction price is allocated to the performance obligations; and (5) revenue is recognized when control of goods or services is transferred to the customer with consideration given, whether that control happens over time or not. Determination of criteria (3) and (4) are based on our management’s judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts.

 

Private Label Customers, Global CBD, LLC and TZ Wholesale, are wholesale distributors of the Company’s product, under their own wholesale private label brand. The products are made to Company specifications and shipped directly to the wholesaler. The pricing is predicated upon a volume discount negotiated at the time of the placement of the orders. Product is produced and labeled in the Washington manufacturing facility and shipped directly to the Private Label customer who re-distributes to their retail and other customers. The products are fully paid when shipped.

 

Revenue from product sales is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured.

 

The Company’s Duramed Division provides a sam® Pro 2.0 medical device to patients through a doctor program whereby the physician evaluates the patients’ needs for medical necessity, and if determined that the device use would be beneficial, writes a prescription for the patient who signs a rental form, for a 35 day cycle for the unit, that is submitted to Duramed who bills the appropriate insurance company. The insurance company pays the invoice, or a negotiated amount via arbitration, and that revenue is reported as revenue when invoiced to the insurance carrier. The collected amount is reconciled with the invoice amount on a daily basis.

 

 

(m) Cost of Product Sales

 

The cost of product sale is the total cost incurred to obtain a sale and the cost of the goods sold, and the Company’s policy is to recognize it in the same manner as, and in conjunction with, revenue recognition. Cost of product sale primarily consisted of the costs directly attributable to revenue recognized and includes expenses related to the production, packaging and labeling of our CBD products.

 

(n) Stock-Based Compensation

 

Stock-based compensation is accounted for at fair value in accordance with Accounting Standards Codification (“ASC”) Topic 718, “Compensation – Stock Compensation” (“ASC718”) and ASC 505-50, “Equity – Based Payments to Non-Employees.” In addition to requiring supplemental disclosures, ASC 718 addresses the accounting for share-based payment transactions in which a company receives goods or services in exchange for (a) equity instruments of the company or (b) liabilities that are based on the fair value of the company’s equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 focuses primarily on accounting for transactions in which a company obtains employee services in share-based payment transactions.

 

In accordance with ASC 505-50, the Company determines the fair value of the stock-based payment as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instrument is reached, or (2) the date at which the counterparty’s performance is complete.

 

Options and warrants

 

The fair value of stock options and warrants is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year:

 

Risk-Free Interest Rate.

 

We utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of our awards.

 

Expected Volatility.

 

We calculate the expected volatility based on a volatility index of peer companies as we did not have sufficient historical market information to estimate the volatility of our own stock.

 

Dividend Yield.

 

We have not declared a dividend on its common stock since its inception and have no intentions of declaring a dividend in the foreseeable future and therefore used a dividend yield of zero.

 

Expected Term.

 

The expected term of options granted represents the period of time that options are expected to be outstanding. We estimated the expected term of stock options by using the simplified method. For warrants, the expected term represents the actual term of the warrant.

 

Forfeitures.

 

Estimates of option forfeitures are based on our experience. We will adjust our estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.

 

 

(o) Advertising

 

Advertising costs are expensed as incurred and amounted to $350,334 and $220,373 for the periods ended September 30, 2020 and 2019, respectively.

 

(p) Research and Development

 

Research and development costs are expensed as incurred. In the period ended September 30, 2020 and 2019, the Company spent $80,000 and $45,000 in research and development which was expenses as spent, respectively.

 

(q) Income Taxes

 

Income taxes are accounted for under the assets and liability method. Current income taxes are provided in accordance with the laws of the respective taxing authorities. Deferred income taxes are provided for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is not more likely than not that some portion or all of the deferred tax assets will be realized.

 

The Company has adopted the provisions required by the Income Taxes topic of the FASB Accounting Standards Codification. The Codification Topic requires the recognition of potential liabilities as a result of management’s acceptance of potentially uncertain positions for income tax treatment on a “more-likely-than-not” probability of an assessment upon examination by a respective taxing authority. The Company believes that it has not taken any uncertain tax positions and thus has not recorded any liability.

 

(r) Net Income (Loss) per Common Share

 

Basic net income (loss) per common share is computed on the basis of the weighted average number of common shares outstanding during the period.

 

Diluted net income (loss) per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation. For the periods presented, the diluted net loss per share calculation excluded the effect of Series B preferred stocks and stock options outstanding (see Notes 10, 11 and 12).

 

(s) Reverse Stock-Split

 

On March 2, 2020, the Company filed an amendment to its Articles of Incorporation with the Florida Secretary of State to effect a 300-to-1 reverse stock split of its issued and outstanding, but not authorized, shares of Common Stock, as reported in the Company’s definitive Schedule 14C filed with the Securities and Exchange Commission on December 13, 2019.

 

All disclosures of common shares and per common share data in the accompanying financial statements and related notes reflect the reverse stock split for all periods presented.

 

(t) Recent Accounting Pronouncements

 

In 2016, the FASB issued ASU 2016-2 (Topic 842) which establishes a new lease accounting model for lessees. Under the new guidance, lessees will be required to recognize right of use assets and liabilities for most leases having terms of 12 months or more. Effective January 1, 2019, we adopted this new accounting guidance using the effective date transition method, which permits entities to apply the new lease standards using a modified retrospective transition approach at the date of adoption.

 

 

(u) Basis of presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six-month period ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ended December 31, 2020.

 

(v) Reclassifications

 

Certain amounts in the prior year consolidated financial statements have been reclassified to conform to the current year presentation. These reclassification adjustments had no effect on the Company’s previously reported net income.

 

NOTE 4 – Inventories

 

Inventories consist of:

 

		September 30, 2020				December 31, 2019
Raw materials		$	900,599			$	708,239
Finished goods			13,530				76,258
Total		$	914,129			$	784,497

 

NOTE 5 – Notes Receivable

 

Notes receivable consist of:

 

		September 30, 2020				December 31, 2019
Note receivable dated November 30, 2015 from Stock Market Manager, Inc, interest at 3% per annum due November 30, 2020		$	19,389			$	19,389
Note receivable dated February 8, 2019 from an employee, weekly installments of $1,200 with interest at 8% per annum.			2,898				4,879
Note receivable dated March 3, 2020 from an employee, weekly installments of $125 with interest at 0% per annum.			500				-
Total			22,787				24,268
Current portion of notes receivable			(22,787	)			(24,268	)
Noncurrent portion of notes receivable		$	-			$	-

 

NOTE 6 – Property and Equipment, Net

 

Property and Equipment, net, consist of:

 

		September 30, 2020				December 31, 2019
Furniture & Fixtures		$	21,724			$	19,018
Office Equipment			12,378				12,378
Manufacturing Equipment			390,627				355,016
Medical Equipment			783,782				783,782
Leasehold Improvements			26,902				21,603
Total			1,235,413				1,191,797
Accumulated depreciation			(209,554	)			(116,555	)
Net		$	1,025,859			$	1,075,242

 

 

NOTE 7 – Intangible Assets, Net

 

Intangible assets, net, consist of:

 

		September 30,				December 31,
		2020				2019
Video conferencing software acquired by Prosperity in December 2009		$	30,000			$	30,000
Enterprise and audit software acquired by Prosperity in April 2008			20,000				20,000
Patent costs incurred by WRAP			6,880				6,880
Hemp license and technology			1,000,000				1,000,000
CBD technology			198,655				198,655
Platform account contract			131,812				-
Hemp processing use			69,375				-
Other			3,548				3,548
Total			1,460,270				1,259,083
Accumulated amortization and Impairment			(649,077	)			(202,521	)
Net		$	811,193			$	1,056,562

 

Estimated future amortization expense are as follows:

 

September 31,		Amount
2021		$	616,837
2022			36,284
2023			36,284
2025			34,599
2026			19,868
Thereafter			67,321
Total		$	811,193

 

The CBD related technology were purchased from Hudilab, Inc. (“HUDI”) and Seven Chakras, LLC (“Seven Chakras”) during the three months ended March 31, 2019. On January 14, 2019, the Company and PHP (collectively, the “buyer”) entered into a License and Acquisition Agreement (the “LAA”) with HUDI. Pursuant to the LAA, HUDI will sell the technology owned by it to the buyer in exchange for 25,000 shares of CANB common stock. On January 14, 2019, the shares were issued to the owner of HUDI and valued at $131,625. On January 31, 2019, PHP entered into an Asset Purchase Agreement (the “Chakras Agreement”) with Seven Chakras. Pursuant to the Chakras Agreement, PHP purchased the rights and title to (i) Seven Chakras’ proprietary formulas, methods, trade secrets, and know-how related to the production of Seven Chakras’ products containing cannabidiol (CBD), (ii) Seven Chakras’ tradename, domain name, and social media sites, and (iii) other assets of Seven Chakras including but not limited to raw materials, equipment, packaging and labeling materials, mailing lists, and marketing materials. On February 20, 2019, the Company issued 3,333 shares of CANB common stock valued at $17,030 to owners of Seven Chakras as additional consideration, along with the $50,000 cash payments, pursuant to the Chakras Agreement.

 

 

The hemp related license and technology was purchased from Shi Farms during the three months ended September 30, 2019. Hemp Depot has remained dormant since the Shi Farms deal was consummated and no activity is contemplated. The Company subsequently acquired Green Grow Farms, also a NY State Hemp License holder and intends to contract with farmers in New York to grow hemp under a controlled program of specific strains, cultured feminized seeds, proven technology, and access to processing for their crop. Grow Farms Inc. intends to amalgamate the cultivated off-take from the farmers, combine and fill “super-sacks” for shipping to a processing facility to produce high-grade isolate or distillate for use in Can B̅’s manufacturing facility in Lacey WA.

 

The hemp processing use agreement with Mediiusa Group, Inc. was entered during the three months ended June 30, 2020. On June 23, 2020, the Company issued 50,000 shares of CANB common stock valued at $69,375. Mediiusa Group, Inc. currently holds a valid Industrial Hemp Processor Registration in full force and effect with the State of New York under Registration: HEMP-P-000035 (the “Registration”) and is authorized to process Hemp, and has granted a five year agreement to processing of Hemp for oil, isolate, or crude for further use by the Company and/or for sale by the Company. During the Term of this Agreement, Mediiusa Group, Inc. agrees to allow CANB to process any and all of the subject Hemp under and/or in connection with the agreement under their above-mentioned Registration.

 

The platform account contract with SRAX, Inc. was entered during the three months ended June 30, 2020. On June 22, 2020, the Company issued 185,000 shares of CANB common stock valued at $131,812. The Platform Account is the SRAX Investors Relations platform to grant access to potential investors and customers via the SRAX website. SRAX grants Can B Corp a non-exclusive, non-transferable and non- sublicensable right to access and use the Platform during the Term, solely by the Authorized Users for User’s own internal business purposes, and in accordance with the terms and conditions of this Agreement. Company reserves all rights in or to the Platform not expressly granted to User in the Agreement. Can B will have previously unattainable access to its customer base for improved investor communication and development of sales opportunities of the Company’s products.

 

The other intangible assets relate to the document management and email marketing divisions. Since December 31, 2017, the Company do not expect any future positive cash flow from these divisions. Accordingly, the net carrying value of these intangible assets was reduced to $0.

 

NOTE 9 – Notes and Loans Payable

 

Notes and loans payable consist of:

 

		September 30, 2020				December 31, 2019
Note payable to brother of Marco Alfonsi, Chief Executive Officer of the Company, interest at 10% per annum, due August 22, 2016 (now past due).		$	5,000			$	5,000
Note payable to FirstFire Global Opportunities Fund, LLC, net of original issue discount of $44,654, due September 1, 2020 (now past due).			550,000				-
Loan payable to Pasquale Ferro, interest at 12% per annum, due December 2020.			138,000				30,000
Note payable to Labrys Fund, LP, net of original issue discount of $21,041, due October 21, 2020 (now past due).			225,000				-
Note payable to EMA Financial, LLC, net of original issue discount of $10,522, due June 17, 2021.			115,000				-
Note payable to Eagle Equities, LLC, net of original issue discount of $27,645, due June 17, 2021.			220,000				-
Note payable to U.S. Small Business Administration (PPP), interest at 1% per annum. The note matures in January 2023. Payments are deferred for ten months after the end of the covered period.			194,940				-
Note payable to U.S. Small Business Administration (EIDL), interest at 3.75% per annum. The note matures in June 2050. Payments are deferred for twelve months.			159,900				-
Loan payable to Senior Management Solutions, interest at 12% per annum, due December 2020.			5,000				-
Total Notes and Loans Payable			1,612,840				35,000
Less: Unamortized Finance Cost			(32,102	)			-
Total Notes and Loans Payable – Net			1,580,738				35,000
Less: Current Portion			(1,225,898	)			(35,000	)
Long-term Portion		$	354,840			$	-

 

 

NOTE 10 – Preferred Stock

 

Each share of Series A Preferred Stock is convertible into 33,334 shares of CANB common stock and is entitled to 66,666 votes. All Preferred Shares shall rank senior to all shares of Common Stock of the Company with respect to liquidation preferences and shall rank pari passu to all current and future series of preferred stock, unless otherwise stated in the certificate of designation for such preferred stock. In the event of a Liquidation Event, whether voluntary or involuntary, each holder may elect (i) to receive, in preference to the holders of Common Stock, a one-time liquidation preference on a per-share amount equal to the per-share value of preferred shares on the issuance date, as recorded in the Company’s financial records, or (ii) to participate pari passu with the Common Stock on an as-converted basis. Subject to any adjustments, the Series A holders shall be entitled to receive such dividends paid and distributions made to the holders of shares of Common Stock on an as converted basis.

 

Each share of Series B Preferred Stock has the first preference to dividends, distributions and payments upon liquidation, dissolution and winding-up of the Company, and is entitled to an accrued cumulative but not compounding dividend at the rate of 5% per annum whether or not declared. After six months of the issuance date, such share and any accrued but unpaid dividends can be converted into common stock at the conversion price which is the lower of (i) $0.0101; or (ii) the lower of the dollar volume weighted average price of CANB common stock on the trading day prior to the conversion day or the dollar volume weighted average price of CANB common stock on the conversion day. The shares of Series B Preferred Stock have no voting rights.

 

Each share of Series C Preferred Stock has preference to payment of dividends, if and when declared by the Company, compared to shares of our common stock. Each Preferred Series C share is convertible into 25,000 shares of common stock. The shares of Series C Preferred Stock have voting rights as if fully converted.

 

On January 28, 2019, the Company issued 33,333 shares of CANB common stock to a consultant of the Company in exchange for the retirement of 1 share of CANB Series A Preferred Stock.

 

From February 21, 2019 to March 12, 2019, the Company issued aggregately 67,405 shares of CANB common stock to RedDiamond in exchange for the retirement of 157,105 shares of CANB Series B Preferred Stock.

 

On May 28, 2019, the Company issued 3 shares of CANB Series A Preferred Stock to Stanley L. Teeple pursuant to the employment agreement with him. The fair value of the issuance totaled $1,203,000 and will be amortized over the vesting period of four years.

 

On April 26, 2019, the Company issued 6,436 shares of CANB common stock to RedDiamond in exchange for the retirement of 15,000 shares of CANB Series B Preferred Stock.

 

 

On May 1, 2019, the Company issued 8,581 shares of CANB common stock to RedDiamond in exchange for the retirement of 20,000 shares of CANB Series B Preferred Stock.

 

On May 9, 2019, the Company issued 23,710 shares of CANB common stock to RedDiamond in exchange for the retirement of 55,263 shares of CANB Series B Preferred Stock.

 

On June 7, 2019, the Company issued 10,726 shares of CANB common stock to RedDiamond in exchange for the retirement of 25,000 shares of CANB Series B Preferred Stock.

 

On August 13, 2019, the Company issued 97,607 shares of CANB common stock to RedDiamond in exchange for the retirement of 227,590 shares of CANB Series B Preferred Stock.

 

On December 16, 2019, the Company issued 35,666 shares of CANB common stock to RedDiamond as agreed for the early retirement of CANB Series B Preferred Stock converted in August 2019.

 

NOTE 11 – Common Stock

 

From January 4, 2019 to March 27, 2019, the Company issued aggregately 138,107 shares of CANB common stock to multiple investors pursuant to relative Stock Purchase Agreements dated on various dates, in exchange for total proceeds of $1,196,100.

 

On January 14, 2019, the Company issued 25,000 shares of CANB common stock to Hudilab, Inc. (“HUDI”), pursuant to a License and Acquisition Agreement for purchase of the technology owned by HUDI.

 

From January 18, 2019 to March 17, 2019, the Company issued aggregately 82,000 shares of CANB common stock to multiple consultants for services rendered.

 

From January 19, 2019 to March 27, 2019, the Company issued aggregately 3,893 shares of CANB common stock to employee and officers of the Company pursuant to employee agreement and in satisfaction of accrued compensation for the quarter ended March 31, 2019.

 

On February 5, 2019, the Company issued 6,667 shares to the owner of TZ Wholesale LLC, pursuant to a Memorandum of Understanding (the “MOU”) dated November 9, 2018.

 

On February 20, 2019, the Company issued 3,333 shares of CANB common stock to owners of Seven Chakras pursuant to the Chakras Agreement dated January 31, 2019.

 

From April 1, 2019 through June 30, 2019 the Company issued an aggregate of 51,706 shares of CANB Common Stock to multiple consultants for services rendered.

 

From April 1, 2019 through June 30, 2019, the Company issued an aggregate of 13,916 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered.

 

From April 1, 2019 through June 30, 2019, the Company issued an aggregate of 4,615 shares of Common Stock under the terms of executive employment agreements.

 

From April 1, 2019 through June 30, 2019, the Company issued an aggregate of 86,207 shares of CANB shares under the terms of the Stock Purchase Agreements for total proceeds of $750,000.

 

From July 1, 2019 through September 30, 2019, the Company issued an aggregate of 18,061 shares of CANB Common Stock to multiple consultants for services rendered.

 

From July 1, 2019 through September 30, 2019, the Company issued an aggregate of 18,333 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered.

 

From July 1, 2019 through September 30, 2019, the Company issued an aggregate of 16,000 shares of Common Stock under the terms of executive employment agreements.

 

 

From July 1, 2019 through September 30, 2019, the Company issued an aggregate of 155,241 shares of CANB shares under the terms of the Stock Purchase Agreements for total proceeds of $1,350,600.

 

From July 1, 2019 through September 30, 2019, the Company issued an aggregate of 40,247 shares of CANB shares under the terms of the Joint Venture Agreement.

 

From October 1, 2019 through December 31, 2019, the Company issued an aggregate of 122,258 shares of CANB Common Stock to multiple consultants for services rendered.

 

From October 1, 2019 through December 31, 2019, the Company issued an aggregate of 14,167 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered.

 

From October 1, 2019 through December 31, 2019, the Company issued an aggregate of 5,000 shares of Common Stock under the terms of executive employment agreements.

 

From October 1, 2019 through December 31, 2019, the Company issued an aggregate of 125,000 shares of CANB Common Stock under the terms of an inventory purchase agreement for total proceeds of $487,500.

 

From January 1, 2020 through March 31, 2020, the Company issued an aggregate of 27,500 shares of CANB Common Stock to multiple consultants for services rendered.

 

From January 1, 2020 through March 31, 2020, the Company issued an aggregate of 31,335 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered.

 

From January 1, 2020 through March 31, 2020, the Company issued an aggregate of 20,000 shares of CANB Common Stock to First Fire Global Opportunities Fund, LLC for a commitment fee pursuant to a junior convertible promissory note purchase agreement.

 

From January 1, 2020 through March 31, 2020, the Company issued an aggregate of 99,508 shares of CANB Common Stock to FirstFire Global Opportunities Fund, LLC for returnable shares pursuant to a junior convertible promissory note purchase agreement.

 

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 111,734 shares of CANB Common Stock to multiple consultants for services rendered.

 

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 20,319 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered.

 

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 30,000 shares of CANB Common Stock to an employee for services rendered.

 

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 185,000 shares of CANB Common Stock to SRAX, Inc. according to a platform access agreement.

 

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 50,000 shares of CANB Common Stock to Mediiusa Group, Inc. according to a hemp processing use agreement.

 

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 24,545 shares of CANB Common Stock to Labrys Fund, L.P. for a commitment fee pursuant to a junior convertible promissory note purchase agreement.

 

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 118,000 shares of CANB Common Stock to Labrys Fund, L.P. for returnable shares pursuant to a junior convertible promissory note purchase agreement.

 

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 20,000 shares of CANB Common Stock to Eagle Equities, LLC for a commitment fee pursuant to a junior convertible promissory note purchase agreement.

 

 

From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 145,000 shares of CANB Common Stock to multiple consultants for services rendered.

 

From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 100,000 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered.

 

From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 478,715 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered.

 

From July 1, 2020 through September 30, 2020, the Company received an aggregate of 543,715 shares of CANB Common Stock from an exchange agreement whereby shares of Iconic Brands, Inc. held by the Company were exchanged for shares of stock in the Company held by Iconic Brands, Inc.

 

From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 478,715 shares of CANB Common Stock for the acquisition of inventory.

 

From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 185,000 shares of CANB Common Stock to FirstFire Global Opportunities Fund, LLC pursuant to a junior convertible promissory note purchase agreement.

 

On July 29, 2020, CANB and Iconic Brands (ICNB) completed a share exchange whereby the one million shares of ICNB common stock held by CANB were exchanged for a fair value exchange of five hundred forty three thousand seven hundred fifteen shares of CANB in order to settle a contract valuation true-up with ICNB for the purchase of Green Grow Farms,. Inc.

 

NOTE 12 – Stock Options and Warrants

 

A summary of stock options and warrants activity follows:

 

		Shares of Common Stock Exercisable Into
		Stock
		Options				Warrants				Total
Balance, December 31, 2019			20,167				7,492				27,659
Granted in 2019			56,667				-				56,667
Cancelled in 2019			(167	)			-				(167	)
Exercised in 2019			-				-				-
Balance, December 31, 2019			76,667				7,492				84,159
Granted in Q1, Q2 & Q3 2020			-				-				-
Cancelled in Q1, Q2 & Q3 2020			-				-				-
Exercised in Q1, Q2 & Q3 2020			-				-				-
Balance, September 30, 2020			76,667				7,492				84,159

 

Issued and outstanding stock options as of September 30, 2020 consist of:

 

Year		Number Outstanding				Exercise				Year of
Granted		And Exercisable				Price				Expiration
2018			20,000			$	0.3				2023
2019			56,667			$	0.3				2022
			76,667

 

 

On June 11, 2018, the Company granted 10,000 options of CANB common stock to Carl Dilley, a former director of the Company, in exchange for the retirement of a total of 10,000 shares of CANB common stock from Carl Dilley. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.30 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire June 11, 2023. The value of the Stock Options ($84,000) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $8.40 share price, (ii) 5 years term, (iii) 262.00% expected volatility, (iv) 2.80% risk free interest rate and the difference between this value and the fair value of retired shares was expensed in the quarterly period ended June 30, 2018.

 

On October 21, 2018, the Company granted 10,000 options of CANB common stock to Stanley L. Teeple, an officer and Director of the Company. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.30 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire October 1, 2023. The values of the Stock Options ($118,200) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $11.82 share price, (ii) 5 years term, (iii) 221.96% expected volatility, (iv) 3.05% risk free interest rate and the fair value of options was expensed in the quarterly period ended December 31, 2018

 

On September 9, 2019, the Company granted 26,667 options of CANB common stock to Johnny Mack, a former officer of the Company. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.30 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire September 9, 2022. The values of the Stock Options ($192,000) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $7.20 share price, (ii) 3 years term, (iii) 242% expected volatility, (iv) 1.46% risk free interest rate and the fair value of options was expensed in the quarterly period ended September 30, 2019.

 

On October 15, 2019, the Company granted 10,000 options of CANB common stock each to Frederick Alger Boyer, Jr., Ronald A. Silver and James F. Murphy, directors of the Company. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.30 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire October 15, 2022. The values of the Stock Options ($63,000 each) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $6.30 share price, (ii) 3 years term, (iii) 242% expected volatility, (iv) 1.60% risk free interest rate and the fair value of options was expensed in the quarterly period ended December 31, 2019.

 

Issued and outstanding warrants as of September 30, 2020 consist of:

 

Year		Number Outstanding				Exercise				Year of
Granted		And Exercisable				Price				Expiration
2010			825			$	300				2020
2018			6,667			$	13.034	(a)			2023
Total			7,492

 

(a) 110% of the closing price of the Company’s common stock on the date that the Holder funds the full purchase price of the Note.

 

NOTE 13 – Income Taxes

 

No provisions for income taxes were recorded for the periods presented since the Company incurred net losses in those periods.

 

The provisions for (benefits from) income taxes differ from the amounts determined by applying the U.S. Federal income tax rate of 21% to pretax income (loss) as follows:

 

		Nine Month Ended September 30,
		2020				2019
Expected income tax (benefit) at 21%		$	(755,624	)		$	(745,732	)
Non-deductible stock-based compensation			288,490				502,103
Non-deductible stock-based interest			81,991				-
Increase in deferred income tax assets
valuation allowance			385,143				243,629
Provision for (benefit from) income taxes		$	-			$	-

 

 

Deferred income tax assets consist of:

 

		September 30,				December 31,
		2020				2019
Net operating loss carryforward		$	1,685,311			$	1,300,168
Valuation allowance			(1,685,311	)			(1,300,168	)
Net		$	-			$	-

 

Based on management’s present assessment, the Company has not yet determined it to be more likely than not that a deferred income tax asset of $1,685,311 attributable to the future utilization of the $8,025,288 net operating loss carryforward as of September 30, 2020 will be realized. Accordingly, the Company has maintained a 100% allowance against the deferred income tax asset in the financial statements at September 30, 2020. The Company will continue to review this valuation allowance and make adjustments as appropriate. The net operating loss carryforward expires in years 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039 and 2040 in the amount of $1,369, $518,390, $594,905, $686,775, $159,141, $151,874, $135,096, $166,911, $311,890, $25,511, $338,345, $381,638, $499,288, $716,858, $1,503,282, and $1,834,015, respectively.

 

Current tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs. Therefore, the amount available to offset future taxable income may be limited.

 

The Company’s U.S. Federal and state income tax returns prior to 2016 are closed and management continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. The statute of limitations on the 2016 tax year returns expired in September 2020.

 

The Company recognizes interest and penalties associated with uncertain tax positions as part of the income tax provision and would include accrued interest and penalties with the related tax liability in the consolidated balance sheets. There were no interest or penalties paid during 2020 and 2019.

 

NOTE 14 – Segment Information

 

The Company has one reportable segment: Durable Equipment Products.

 

The accounting policies of the segment described above are the same as those described in Summary of Significant Accounting Policies in Note 3. The Company evaluates the performance of the Durable Equipment Products segment based on income (loss) before income taxes, which includes interest income.

 

		Durable Equipment Products
Six months ended June 30, 2020
Revenue from external customers			527,942
Revenue from other segments			-
Segment profit			278,337
Segment assets			2,228,575
Nine months ended September 30, 2020
Revenue from external customers			808,547
Revenue from other segments			-
Segment profit			415,256
Segment assets			2,369,177

 

 

 

		Three Months Ended September 30, 2020				Nine Months Ended September 30, 2020
Total profit for reportable segment		$	136,919			$	416,109
Other income (expense) - net			-				(853	)
Income before income taxes		$	136,919			$	415,256

 

NOTE 15 – Commitments and Contingencies

 

Employment Agreements

 

On October 3, 2017, the Company executed an Executive Employment Agreement with Marco Alfonsi (“Alfonsi”) for Alfonsi to serve as the Company’s chief executive officer and interim chief financial officer and secretary for cash compensation of $10,000 per month. Pursuant to the agreement, the Company issued a share of CANB Series A Preferred Stock to Alfonsi on October 4, 2017. Alfonsi may terminate his employment upon 30 days written notice to the Company. The Company may terminate Alfonsi’s employment upon written notice to Alfonsi by a vote of the Board of Directors. At October 21, 2018, this former agreement was terminated due to the execution of a new Employment Agreement with Marco Alfonsi for Alfonsi to serve as the Company’s chief executive officer and chairman of the board for cash compensation of $15,000 per month. Pursuant to the new agreement, three of the eight previously issued shares of CANB Series A Preferred Stock were returned to the Company and converted into 30,000,000 common shares. Alfonsi may terminate his employment upon 30 days written notice to the Company. The new agreement has an initial term of four years and can be terminated upon the resignation or death of Mr. Alfonsi, and also can be terminated by the Company due to the failure or neglect of Mr. Alfonsi to perform his duties, or due to the misconduct of Mr. Alfonsi in connection with the performance.

 

On February 12, 2018, the Company executed an Executive Service Agreement (“Posel Agreement”) with David Posel. The Posel Agreement provides that Mr. Posel services as the Company’s Chief Operating Officer for a term of 4 years. The Posel Agreement also provides for compensation to Mr. Posel of $5,000 cash per month and the issuance of 1 share of Series A Preferred Stock at the inception of the Posel Agreement. The Posel Agreement can be terminated upon the resignation or death of Mr. Posel, and also can be terminated by the Company due to the failure or neglect of Mr. Posel to perform his duties, or due to the misconduct of Mr. Posel in connection with the performance. On February 12, 2018, 1 share of CANB Series A Preferred Stock were issued to Mr. Posel. Since execution of the Posel Agreement, Mr. Posel has been re-assigned to COO for Pure Health Products, the Company’s subsidiary.

 

On February 16, 2018, the Company executed an Executive Service Agreement (“Holtmeyer Agreement”) with Andrew W. Holtmeyer. The Holtmeyer Agreement provides that Mr. Holtmeyer serves as the Company’s Executive Vice President Business for a term of 3 years. The Holtmeyer Agreement also provides for compensation to Mr. Holtmeyer of $10,000 cash per month and the issuance of 3, 2 and 1 share of Series A Preferred Stock at the beginning of each year. The Holtmeyer Agreement can be terminated upon the resignation or death of Mr. Holtmeyer, and also can be terminated by the Company due to the failure or neglect of Mr. Holtmeyer to perform his duties, or due to the misconduct of Mr. Holtmeyer in connection with the performance. At December 29, 2018, this Holtmeyer Agreement was terminated due to the execution of a new Employment Agreement with Andrew W Holtmeyer. The second agreement provides that Mr. Holtmeyer serves as the Company’s Executive Vice President Business for a term of 4 years. The second agreement also provides for compensation to Mr. Holtmeyer of $15,000 cash per month and the issuance of 829 shares of common stock upon signing of the agreement. Effective April 1, 2020, Mr. Holtmeyer’s compensation was changed to a straight commission on sales and collection based upon his efforts in lieu of any base compensation. He also will receive no further Company benefits but does retain his previously issued five shares of Series Preferred A Stock.

 

 

On October 15, 2018, the Company executed an Employment Agreement (“Teeple Agreement”) with Stanley L. Teeple. The Teeple Agreement provides that Mr. Teeple services as the Company’s Chief Financial Officer and Secretary for a term of 4 years. The Teeple Agreement also provides for compensation to Mr. Teeple of $15,000 cash per month and the issuance of 1 share of Series A Preferred Stock proportionately vesting over four years beginning December 31, 2018 upon execution of the Teeple Agreement. The Teeple Agreement can be terminated upon the resignation or death of Mr. Teeple, and also can be terminated by the Company due to the failure or neglect of Mr. Teeple to perform his duties, or due to the misconduct of Mr. Teeple in connection with the performance. In May 2019 Mr. Teeple was granted an additional 3 shares of Series A Preferred.

 

On December 28, 2018, the Company executed an Employment Agreement (“Ferro Agreement”) with Pasquale Ferro for Mr. Ferro to serve as Pure Health Products’ president for cash compensation of $15,000 per month and the total issuance of 5 share of Series A Preferred Stock proportionately vesting at the beginning of each year for a term of 4 years. Mr. Ferro may terminate his employment upon 30 days written notice to the Company. The Ferro Agreement has an initial term of four years and can be terminated upon the resignation or death of Mr. Ferro, and also can be terminated by the Company due to the failure or neglect of Mr. Ferro to perform his duties, or due to the misconduct of Mr. Ferro in connection with the performance.

 

Effective September 6, 2019 (the “Effective Date”), Can B̅ Corp. (the “Company” or “CANB”) approved the appointment of Johnny J. Mack (“Mack”) as its President and Chief Operating Officer. Mack had been serving as the Company’s interim COO. The Company and Mack have entered into a new Employee Services Agreement (the “Mack Agreement”) to memorialize the terms of the foregoing. In consideration for Mack’s services, Mack would (i) receive a base salary of $15,000 per month, subject to increase after each yearly anniversary of the Agreement, (ii) be eligible to receive annual cash or stock bonuses, (iii) be entitled to four weeks’ vacation time and five paid days for illness in accordance with the Company’s policies, and (iv) receive a total of 106,667 options (“Mack Options”) to purchase shares of the Company’s common stock, with 26,667 Mack Options vesting on the effective date and additional tranches of 26,667 Mack Options vesting on each of the first, second, and third anniversaries of the Effective Date, assuming Mack’s continued employment. Each Option is exercisable at a price of $0.30 per share. The Company also agreed to hold harmless and indemnify Mack as authorized or permitted by law and the Company’s governing documents, as the same may be amended from time to time, except for acts constituting negligence or willful misconduct by Mack. The Company agreed to pay Mack a severance in the event the Mack Agreement is terminated by the Company without cause or by Mack for “good reason” or by reason of Mack’s death or disability. On October 4, 2019 Mack resigned from all of his officer and director positions and the Company settled his termination for payment of all accrued expenses, payout of all accrued time and base compensation of $13,315 and retention of his already earned 26,667 options. Mr. Mack has left the Company.

 

In addition, on October 10^th, 2019 the Company appointed Philip Scala as its interim COO. Mr. Scala has acted as founder and CEO of Pathfinder Consultants International, Inc. (“Pathfinder”) since 2008. Pathfinder offers unique expertise and delivers the information you need to make informed decisions, whether in times of crisis or in the course of simply running your business. Prior to forming Pathfinder, Mr. Scala served the United States both as a Commissioned Officer in the US Army for five years followed by his 29 years of service with the FBI. Mr. Scala received his bachelor’s degree and Master of Business Administration in accounting from St. John’s University, he also earned a Master of Arts degree in Psychology from New York University. The Company has entered into an employment agreement with Mr. Scala. Pursuant to the agreement, Mr. Scala will receive a base salary of $2,500 per month. He will be entitled to incentive bonuses and pay increases in accordance with the Company’s normal policies and procedures. Mr. Scala will also receive options to buy 1,667 common shares of the Company at a price of $0.30 for a period of three years. The initial term of the agreement is for 90 days. The agreement renews for additional 90-day periods unless terminated by either party. The agreement otherwise contains standard covenants and conditions.

 

Consulting Agreements

 

On July 15, 2020, we engaged an advisor to provide consulting services under an Investor Relations and Advisory Agreement (the “Advisory Agreement”). Pursuant to the Advisory Agreement, we agreed to pay the Consulting Firm a restricted common stock monthly fee of $5,000 per month for the initial 3 months., $6,250 per month for months 4-6., $7,500 per month for month 7 and after. At CANB’s option, the monthly fee may be payable in part or in whole in cash. Monthly Fee, such amount shall be paid via issuance of restricted common shares of CANB. The shares are to be issued in the name of Tysadco Partners. The number of common shares earned each month shall be calculated and issued on a quarterly basis prior to each 90-day period and based on the value at the closing price on the last day of the preceding period. All common shares earned by the Consultant pursuant to this Agreement shall be issued by CANB on a quarterly basis. CT shall not have registration rights, and the shares may be sold subject to Rule 144.

 

 

On December 8, 2019, the Company executed a Consulting Agreement with Seacore Capital, Inc. (“Seacore”) for Seacore to serve as the Company’s consultant for stock compensation of a total of 8,333 restricted shares each quarter from 4^th quarter 2019 through 3^rd quarter 2020. The shares shall not have registration rights, and the shares may be sold subject to Rule 144.

 

Lease Agreements

 

On December 1, 2014, Prosperity entered into a lease agreement with KLAM, Inc. for office space in Hicksville, New York for an initial term of one year commencing December 1, 2014. The lease provides for monthly rentals of $2,500 and provides Prosperity an option to renew the lease after the initial term. The Company has continued to occupy this space after November 30, 2015 under a month to month arrangement at $2,500 per month. This lease was terminated in January 2019.

 

On September 11, 2015, the Company executed a lease agreement with an unrelated third party for office space in Hicksville, New York for a term of 37 months. The lease provides for monthly rentals of $2,922 for lease year 1, $3,009 for lease year 2, and $3,100 for lease year 3. The lease also provides for additional rent based on increases in base year operating expenses and real estate taxes. On August 6, 2018, the Company renewed the lease agreement for a term of 36 months starting November 1, 2018. The lease provides for monthly rentals of $3,193 for lease year 1, $3,289 for lease year 2, and $3,388 for lease year 3. In October 2019, the Company modified and extended the lease agreement for a term of 30 months starting November 1, 2019. The lease provides for monthly rentals of $3,807 for year 1 and $3,921 for the remaining eighteen months. The original $100,681 right-of-use asset and $90,591 lease liability was adjusted to $103,260 with the modification.

 

The Company leases office space in numerous medical facilities under month-to-month agreements.

 

Rent expense for the period ended September 30, 2020 and 2019 was $193,069 and $155,192, respectively.

 

At September 30, 2020, the future minimum lease payments under non-cancellable operating leases were:

 

Year ended December 31, 2020		$	11,650
Year ended December 31, 2021			47,055
Year ended December 31, 2022			15,685
Total		$	74,390

 

The lease liability of $69,100 at September 30, 2020 as presented in the Consolidated Balance Sheet represents the discounted (at our 10% estimated incremental borrowing rate) value of the future lease payments of 74,390 at September 30, 2020.

 

Major Customers

 

For the nine months ended September 30, 2020, there were no customers that accounted for more than 10% of total revenues.

 

For the nine months ended September 30, 2019, there were no customer accounted for more than 10% of total revenues.

 

NOTE 16 – Related Party Transactions

 

LI Accounting Associates, LLC (LIA), an entity controlled by a relative of the Managing Member PHP, is a vendor of CANB. At September 30, 2020, CANB has an account payable due to LIA totaling $9,500. For the nine months ended September 30, 2020, CANB had expenses to LIA of $54,500.

 

During the nine months ended September 30, 2020, we had products and service sales to related parties totaling $0.

 

NOTE 17 – Subsequent Events

 

In accordance with FASB ASC 855, Subsequent Events, the Company has evaluated subsequent events through November 9, 2020, the date on which these consolidated financial statements were available to be issued. There were no material subsequent events that required recognition or additional disclosure in these consolidated financial statements.

 

On November 3, 2020, Steve Apolant was terminated and his duties for Green Grow Farms, Inc. have been assumed directly by CANB CEO Marco Alfonsi.

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Can B̅ Corp. was originally formed as a Florida corporation on October 11, 2005, under the name of WrapMail, Inc. Effective January 5, 2015, we acquired 100% ownership of Prosperity Systems, Inc., which the Company is in the process of dissolving. Effective December 28, 2018, we acquired 100% ownership of Pure Health Products. In November 2018, we formed Duramed, Inc. as a wholly-owned subsidiary. In May 2019, we formed DuramedNJ, LLC and Radical Tactical LLC, as wholly-owned subsidiaries. In July 2019, we formed NY Hemp Depot LLC, as a wholly-owned subsidiary. In August 2019, we acquired Green Grow Farms, Inc., as a wholly-owned subsidiary.

 

We manufacture and sell lifestyle health and wellness products, such as oils, creams, moisturizers, isolate, gel caps, spa products, and concentrates, both containing and void of CBD, which we sell directly and through distributors. Through our Duramed division, we supply medical devices for use via doctor prescriptions for post-surgery and accident patients. Our subsidiary, Green Grow Farms, intends to contract with farmers in New York to grow hemp under a controlled program of specific strains, cultured feminized seeds, proven technology, and access to processing for their crop. Green Grow Farms Inc. intends to amalgamate the cultivated off-take from the farmers, combine and fill “super-sacks” for shipping to a processing facility to produce high-grade isolate or distillate for use in Can B̅’s manufacturing facility in Lacey WA. We also have previously provided document, project, marketing and sales management systems to our residual business clients through our website and proprietary software, which operations are being wound down. The consolidated financial statements include the accounts of CANB and its wholly owned subsidiary Pure Health Products, wholly owned Green Grow Farms, Inc, and wholly owned Duramed subsidiaries.

 

Results of Operations

 

Three months ended September 30, 2020 compared with three months ended September 30, 2019.

 

Revenues decreased $155,926 from $615,422 in 2019 to $459,496 in 2020. The decrease was due to the impact of the COVID-19 outbreak.

 

Cost of product sales decreased $71,469 from $141,850 in 2019 to $70,381 in 2020 due to the reduction in sales caused by the COVID-19 outbreak.

 

Officers and director’s compensation and payroll taxes decreased $66,333 from $442,898 in 2019 to $376,565 in 2020. The 2019 expense amount ($442,898) includes additional stock-based compensation of ($184,556) pursuant to their respective employment agreements. The 2020 expense amount ($376,565) includes additional stock-based compensation of ($293,715) pursuant to their respective employment. The decrease was due to the impact of the COVID-19 outbreak.

 

Consulting fees decreased $312,894 from $449,355 in 2019 to $136,461 in 2020. The 2019 expense amount ($449,355) includes stock-based compensation of $418,267, resulting from stock issued for the service of consultants. The 2020 expense amount ($136,461) includes stock-based compensation of $104,261, resulting from stock issued for the service of consultants.

 

Advertising expense increased $23,688 from $66,611 in 2019 to $90,299 in 2020.

 

Hosting expense increased $1,979 from $3,472 in 2019 to $5,451 in 2020.

 

Rent expense increased $3,897 from $67,520 in 2019 to $71,417 in 2020.

 

Professional fees decreased $6,169 from $82,452 in 2019 to $76,283 in 2020.

 

Depreciation of property and equipment increased $1,097 from $3,157 in 2019 to $4,254 in 2020.

 

Amortization of intangible assets increased $164,431 from $4,967 in 2019 to $169,398 in 2020.

 

Reimbursed expenses decreased $49,934 from $70,905 in 2019 to $20,971 in 2020.

 

Other operating expenses decreased $6,847 from $217,499 in 2019 to $210,652 in 2020.

 

 

Net loss increased $292,077 from $941,099 in 2019 to $1,233,176 in 2020. The decrease was due to the $247,085 decrease in total operating expenses offset by the $452,760 increase in other expense – net, the $1,945 increase in provision for income taxes and the $84,457 decrease in gross profit.

 

Nine months ended September 30, 2020 compared with nine months ended September 30, 2019.

 

Revenues decreased $531,874 from $1,766,161 in 2019 to $1,234,287 in 2020. The decrease was due to the impact of the COVID-19 outbreak.

 

Cost of product sales decreased $463,632 from $703,607 in 2019 to $239,975 in 2020 due to the reduction in sales caused by the COVID-19 outbreak.

 

Officers and director’s compensation and payroll taxes decreased $411,364 from $1,717,586 in 2019 to $1,306,222 in 2020. The 2019 expense amount ($1,717,586) includes additional stock-based compensation of ($1,018,786) pursuant to their respective employments. The 2020 expense amount ($1,306,222) includes additional stock-based compensation of ($916,386) pursuant to their respective employment agreements.

 

Consulting fees decreased $980,958 from $1,540,441 in 2019 to $559,483 in 2020. The 2019 expense amount ($1,540,441) includes stock-based compensation of $1,372,181, resulting from stock issued for the service of consultants. The 2020 expense amount ($559,483) includes stock-based compensation of $457,377, resulting from stock issued for the service of consultants.

 

Advertising expense increased $129,961 from $220,373 in 2019 to $350,334 in 2020.

 

Hosting expense increased $6,198 from $11,389 in 2019 to $17,587 in 2020.

 

Rent expense increased $37,877 from $155,192 in 2019 to $193,069 in 2020.

 

Professional fees increased $206,951 from $194,468 in 2019 to $401,419 in 2020.

 

Depreciation of property and equipment increased $3,670 from $8,687 in 2019 to $12,357 in 2020.

 

Amortization of intangible assets increased $434,429 from $12,127 in 2019 to $446,556 in 2020.

 

Reimbursed expenses decreased $106,326 from $168,260 in 2019 to $61,934 in 2020.

 

Other operating expenses increased $70,678 from $578,775 in 2019 to $649,453 in 2020.

 

Net loss increased $47,104 from $3,551,104 in 2019 to $3,598,208 in 2020. The decrease was due to the $608,884 decrease in total operating expenses offset by the $584,576, increase in other expense – net, the $3,170 increase in provision for income taxes and the $68,242 decrease in gross profit.

 

Liquidity and Capital Resources

 

At September 30, 2020, the Company had cash and cash equivalents of $45,506 and a working capital of $1,882,926. Cash and cash equivalents decreased $1,034 from $46,540 at December 31, 2019 to $45,506 at September 30, 2020. For the nine months ended September 30, 2020, $916,385 was provided by financing activities, $875,284 was used in operating activities, and $42,135 was used in investing activities.

 

The Company currently has no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources although it is in negotiations with a senior secured lender to replace all of the current convertible notes which expire prior to the end of the year..

 

We currently have no commitments with any person for any capital expenditures other than a 2021 commitment for marketing, sales, and royalty payments to Lifeguard Licensing in the amount of $360,000

 

We have no off-balance sheet arrangements.

 

 

Trend Information

 

The novel coronavirus disease of 2019 (“COVID-19”) outbreak has affected the Company’s operations as set forth above. The full impact of the COVID-19 outbreak continues to evolve. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. Management is actively monitoring the impact of the global situation on our financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 outbreak on our results of operations, financial condition, or liquidity for the foreseeable future, however, as a direct result of medical offices closure in our primary area of operations, our sales for third quarter are down approximately 60% year over year and quarter over quarter. During the course of the pandemic situation, the Company laid off 80% of its workforce in the CBD business and are just now recovering those operations. Our inventory increased to over $500,000 due to lack of sales, but fortunately, the product shelf life exceeds two years so as sales increase, we expect inventory levels to level off at close to $200,000. Our Duramed division was tasked with 90% of the affiliate doctors ceasing operations for period from 4-8 months and are just now recovering full operations. Presently, our Duramed operations are at 60% of pre-COVID operational level. Our expectation that as business open, and in particular medical offices, that our recovery will progress in sync with the speed of the business openings and expect to be back to pre-COVID operational level by end of the 1^st quarter 2021.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

None.

 

ITEM 4. CONTROLS AND PROCEDURES

 

(A) EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

 

As of September 30, 2020, our principal executive officer and principal financial officer conducted an evaluation regarding the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act). Based upon the evaluation of these controls and procedures, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report.

 

(B) CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

 

There were no changes in our internal control over financial reporting in our fiscal quarter for the period September 30, 2020 covered by this Quarterly Report on Form 10-Q, that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

 

PART II-OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We are not currently a party to any legal proceedings.

 

ITEM 1A. RISK FACTORS

 

As a smaller reporting company, we are not required to provide risk factors in this Form 10-Q, however The Company has been directly impacted and has experienced moderate interruption during this challenging COVID-19 pandemic. In accordance with applicable federal and state guidelines, the Company has implemented and prioritized strict social distancing measures, good manufacturing practices, proper sanitization measures, and new manufacturing guidelines. Although several Company customers have experienced business shutdowns during the last few weeks, this has dramatically impacted our online ordering and/or initiating new direct shipment orders. Additional COVID operating requirements to insure safety, handling requirements, sanitation requirements have placed a significant burden on order processing and fulfilment.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Sales of unregistered securities during the nine months ended September 30, 2020 are as follows:

 

From January 1, 2020 through March 31, 2020, the company issued an aggregate of 27,500 shares of CANB Common Stock to multiple consultants for services rendered.

 

 

From January 1, 2020 through March 31, 2020, the company issued an aggregate of 31,335 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered.

 

From January 1, 2020 through March 31, 2020, the company issued an aggregate of 20,000 shares of CANB Common Stock to FirstFire Global Opportunities Fund, LLC for a commitment fee pursuant to a junior convertible promissory note purchase agreement.

 

From January 1, 2020 through March 31, 2020, the company issued an aggregate of 99,508 shares of CANB Common Stock to FirstFire Global Opportunities Fund, LLC for returnable shares pursuant to a junior convertible promissory note purchase agreement.

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 111,734 shares of CANB Common Stock to multiple consultants for services rendered.

 

From April 1, 2020 through June 30, 2020, the company issued an aggregate of 20,319 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered.

 

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 30,000 shares of CANB Common Stock to an employee for services rendered.

 

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 185,000 shares of CANB Common Stock to SRAX, Inc. according to a platform access agreement.

 

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 50,000 shares of CANB Common Stock to Mediiusa Group, Inc. according to a hemp processing use agreement.

 

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 24,545 shares of CANB Common Stock to Labrys Fund, L.P. for a commitment fee pursuant to a junior convertible promissory note purchase agreement.

 

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 118,000 shares of CANB Common Stock to Labrys Fund, L.P. for returnable shares pursuant to a junior convertible promissory note purchase agreement.

 

From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 20,000 shares of CANB Common Stock to Eagle Equities, LLC for a commitment fee pursuant to a junior convertible promissory note purchase agreement.

 

From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 145,000 shares of CANB Common Stock to multiple consultants for services rendered.

 

From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 100,000 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered.

 

From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 478,715 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered.

 

From July 1, 2020 through September 30, 2020, the Company received an aggregate of 543,715 shares of CANB Common Stock from an exchange agreement whereby shares of Iconic Brands, Inc. held by the Company were exchanged for shares of stock in the Company held by Iconic Brands, Inc.

 

From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 60,000 shares of CANB Common Stock for the acquisition of inventory.

 

 

From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 185,000 shares of CANB Common Stock to FirstFire Global Opportunities Fund, LLC pursuant to a junior convertible promissory note purchase agreement.

 

With respect to the transactions noted above, each of the recipients of securities of the Company was an accredited investor, or is considered by the Company to be a “sophisticated person”, inasmuch as each of them has such knowledge and experience in financial and business matters that they are capable of evaluating the merits and risks of receiving securities of the Company. No solicitation was made and no underwriting discounts were given or paid in connection with these transactions. The Company believes that the issuance of its securities as described above was exempt from registration with the Securities and Exchange Commission pursuant to Section 4(a)(2) and/or Regulation D of the Securities Act of 1933.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBITS

 

3.1A		Articles of Incorporation, as amended(1)
3.1B		Articles of Amendment with Series C Certificate of Designation(3)
3.2		Bylaws(2)
10.1		Hemp processing use agreement with Mediiusa Group, Inc.
10.2		Platform Account Contract with SRAX, Inc.
10.3		Convertible Promissory Note with FirstFire Global Opportunities Fund, LLC(4)
10.4		Convertible Promissory Note with Eagle Equities, LLC(5)
10.5		Convertible Promissory Note with EMA Financial, LLC(5)
10.6		Convertible Promissory Note with Labrys Fund, LP(6)
10.7		License Agreement with Lifeguard Licensing Corp(7)
31.1		Chief Executive Officer certification under Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Chief Financial Officer certification under Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Chief Executive Officer certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Chief Financial Officer certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

(1)		Filed with the Annual Report on Form 10-K filed with the SEC on April 2, 2020 and incorporated herein by reference.
(2)		Filed with the Form S-1 Registration Statement filed with the SEC on December 2, 2015 and incorporated herein by reference.
(3)		Filed with the Quarterly Report on Form 10-Q filed with the SEC on August 19, 2020 and incorporated herein by reference.
(4)		Filed with the Current Report on Form 8-K filed with the SEC on January 14, 2020 and incorporated herein by reference.
(5)		Filed with the Current Report on Form 8-K filed with the SEC on June 24, 2020 and incorporated herein by reference.
(6)		Filed with the Form 1-A/A Offering Statement filed with the SEC on July 17, 2020 and incorporated herein by reference.
(7)		Filed with the Current Report on Form 8-K filed with the SEC on February 18, 2020 and incorporated herein by reference.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	Can B Corp.
Date: November 16, 2020	By:	/s/ Marco Alfonsi
		Marco Alfonsi, Chief Executive Officer
Date: November 16, 2020	By:	/s/ Stanley L. Teeple
		Stanley L. Teeple, Chief Financial Officer